{"entity":{"id":"nct04437160","kind":"trial","name":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","aka":[],"tldr":"A phase 2 trial of epirubicin, pirarubicin and cyclophosphamide in triple-negative breast cancer, run by Chinese Academy of Medical Sciences, now recruiting.","summary":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy is a phase 2, randomised interventional study registered as NCT04437160 by Chinese Academy of Medical Sciences, with a registry enrolment figure of 286 participants, started 2020-02-01 and due to reach its primary completion in 2026-01. Interventions recorded: Epirubicin or Pirarubicin; Cyclophosphamide. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Triple negative breast cancer: hormone receptor negative (ER \\< 10% and PgR \\< 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04437160","url":"https://clinicaltrials.gov/study/NCT04437160"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["epirubicin","pirarubicin","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04437160","phase":"2","setting":"A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Efficacy and Safety of Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Platinum-based Neoadjuvant Chemotherapy","sponsor":"Chinese Academy of Medical Sciences","enrolled":286,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04437160/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/"},{"id":"pirarubicin","kind":"drug","name":"Pirarubicin","route":"/drugs/pirarubicin/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}